Jennerex Biotherapeutics, ULC is a clinical-stage cancer therapeutics company.

We create and develop a new class of cancer treatment products called oncolytic viruses (�onco� cancer, �lytic� destructive).

We engineer these therapeutic viruses to target genetic pathways that are critical to the vast majority of human cancers.

Our products have a novel primary mechanism-of-action that is effective against cancers that are resistant to standard chemotherapies/therapies.

In addition, we can arm our products with therapeutic payloads that destroy cancers by complementary and synergistic mechanisms.

As a result, our products wage a multi-pronged attack on cancer.

We have three products in clinical development.

Our lead product JX-594 is entering Phase II clinical trials, and it has already demonstrated promising safety, mechanistic proof-of-concept and anti-cancer activity in patients.